Tokai has announced that their Phase III trial of Galeterone vs. Xtandi for patients with AR-V7 tumors has been suspended. An Independent data monitoring committee has "determined that the ARMOR3-SV trial will likely not succeed in meeting its primary endpoint of demonstrating an improvement in radiographic progression-free survival (rPFS) for galeterone versus enzalutamide in AR-V7 positive mCRPC"
www.businesswire.com/news/home/20160726005553/en/Tokai-Pharmaceuticals-Announces-Clinical-UpdateSo far, the ARMOR2, a Phase II trial of galeterone for people who have failed Xtandi and Zytiga and are mCRPC, continues.
It's disappointing to read this, given how much optimism was generated about
Galeterone and AR-V7.
But, does this mean that galeterone could still be shown to be effective for people who have failed other treatments? In other words, is the end of the road, or is it the end for only the AR-V7 trial?
Arthur